Hjem › Nasofaryngealt karcinom
Kliniske studier for Nasofaryngealt karcinom rekrutterer i USA
13 studier for Nasofaryngealt karcinom rekrutterer deltakere på steder over hele USA.
Byer med flest studier
- Atlanta, GA6 studier
- Pittsburgh, PA3 studier
- Houston, TX3 studier
- Milwaukee, WI3 studier
- Oklahoma City, OK3 studier
- Cincinnati, OH3 studier
- Charlotte, NC3 studier
- Chicago, IL3 studier
- Washington, DC3 studier
- Los Angeles, CA3 studier
- San Francisco, CA3 studier
- Richmond, VA3 studier
Etter delstat
- California6 studier
- Georgia6 studier
- Illinois3 studier
- Maryland3 studier
- Missouri3 studier
- North Carolina3 studier
- Ohio3 studier
- Oklahoma3 studier
- Pennsylvania3 studier
- South Carolina3 studier
- Texas4 studier
- Virginia4 studier
- Wisconsin3 studier
Nylig oppdaterte studier
Offisiell studietekst (engelsk)
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
RekruttererFase 1
Alder 18 til 120 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06479811Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06980038Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 16. sep. 2026 · NCT06029270A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
RekruttererFase 2
Opp til 21 år · Alle kjønn · Oppdatert 14. sep. 2026 · NCT06064097Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 17. aug. 2026 · NCT06532279A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 6. aug. 2026 · NCT07749586Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 16. jul. 2026 · NCT06662058Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 15. jul. 2026 · NCT01365169Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 23. jun. 2026 · NCT06592599Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 17. jun. 2026 · NCT06682442Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 15. apr. 2026 · NCT03010150TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 4. mar. 2026 · NCT06868433Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 11. feb. 2026 · NCT06636734Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.